Along side leading Big Pharma companies Atrogi participated in the 58th European Association for the Study of Diabetes (EASD) Annual meeting in Stockholm!
Category: In the News
New patent granted
Atrogi is developing novel compounds and treatments of metabolic disorders and a robust patent portfolio has been generated to develop the commercial asset and increase value. Several patents have already been granted; here are two of the more recent from June and August.
US 11,357,757
Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycemia
US 11,427,539
Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycemia
BIO-Europe 2017 in Berlin
Atrogi meets several pharmaceutical companies
Atrogi participated in BIO-Europe 2017 in Berlin, which is the largest partnering meeting in Europe. The purpose was to present our type 2 diabetes project to pharmaceutical companies. At the meeting Atrogi met with several of the largest companies that are working in the diabetes area. The response was overwhelming and Atrogi will follow up the requests for information.
Second patent granted
One of Atrogis patent application was granted in the US (US 9,784,726). The patent describes inventions useful for finding compounds for the treatment of diseases such as type 2 diabetes. This was the second time such a patent was granted.
5MSEK fund granted
Atrogi was awarded a 5 MSEK grant. This very prestigeful grant from the SWElifes accelerator program was received in fierce competition with other applicants. The grant will be used to help bring one of the compounds that Atrogis is developing for the treatment of type 2 diabetes to the clinic.
